CSIMarket Company Name, Ticker, Suppliers, else..
 
Y mabs Therapeutics inc   (NASDAQ: YMAB)
 
Price: $8.6100 $0.02 0.233%
Day's High: $8.61 Week Perf: 0.35 %
Day's Low: $ 8.59 30 Day Perf: 1.18 %
Volume (M): 760,600 52 Wk High: $ 8.61
Volume (M$): $ 6,549 52 Wk Avg: $8.61
Open: $8.59 52 Wk Low: $8.59



 Market Capitalization (Millions $) 390
 Shares Outstanding (Millions) 45
 Employees 100
 Revenues (TTM) (Millions $) 85
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 0

Business Description


Ymabs Therapeutics Inc. is a biopharmaceutical company that focuses on developing innovative antibody-based therapies for the treatment of cancer. The company specializes in the development of monoclonal antibodies that target specific tumor types and aims to improve patient outcomes by providing more effective and personalized treatment options. Ymabs Therapeutics takes a precision medicine approach, utilizing advanced technologies to identify and develop therapies that have the potential to selectively kill cancer cells while sparing healthy tissues. Its pipeline includes several promising drug candidates in various stages of development, with a focus on pediatric oncology. The company is committed to advancing medical science and making a meaningful impact in the lives of patients with cancer.


   Company Address: 202 Carnegie Center Princeton 8540 NJ
   Company Phone Number: 885-8505   Stock Exchange / Ticker: NASDAQ YMAB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AZN   -3.17%    
BMY   -6.83%    
JNJ   -3.42%    
LLY   -3.53%    
MRK   -5.04%    
NVS   -15.67%    
• View Complete Report
   



Product Service News

Progress and Challenges in the GD2-SADA PRIT Trial Insights from Y-mAbs Therapeutics at ANR 2025

Published Tue, May 27 2025 11:00 AM UTC

Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a biopharmaceutical company dedicated to pioneering advancements in cancer treatment through radioimmunotherapy and antibody-based products, recently presented a trial in progress poster at the Advances in Neuroblastoma Research Meeting (ANR) held from May 25-28, 2025, in Washington, D.C. This poster highlighted their GD2-SADA PRIT (...
Clinical Study

Preclinical GD2-SADA Data to Revolutionize Cancer Treatment: A Comprehensive Analysis

Published Fri, Jun 7 2024 11:05 AM UTC

Y-mAbs Therapeutics, a pioneering biopharmaceutical company dedicated to advancing novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has recently unveiled groundbreaking preclinical data on GD2-SADA. This exciting revelation holds immense promise for the future of cancer treatment. The Society of Nuclear Medicine & Molecular Imaging (SNMM...
Clinical Study

Y-mAbs Reports Encouraging Interim Phase 2 Data for Naxitamab in High-Risk Neuroblastom...

Published Sat, Jun 1 2024 12:05 PM UTC

Y-mAbs Announces Promising Phase 2 Data for Naxitamab in the Treatment of High-Risk NeuroblastomaNEW YORK, June 01, 2024 - Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a leading biopharmaceutical company specializing in the development and commercialization of innovative radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has disclosed new interim d...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4.61
Price to Sales (Expected) -
Price to Book 4.46
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.71
Working Capital Ratio 4
Leverage Ratio (MRQ) 0.34
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.5 $
Revenues (TTM) 1.87 $
Cash Flow (TTM) -
Cash 1.37 $
Book Value 1.93 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 847,210
Net Income per Employee (TTM) -222,230
Receivable Turnover Ratio (TTM) 4.64
Inventory Turnover Ratio (TTM) 1.73
Asset Turnover Ratio (TTM) 0.73

Profitability Ratios Current
Gross Margin (MRQ) 89.4 %
Operating Margin (MRQ) -29.71 %
Net Margin (MRQ) -17.17 %
Net Cash Flow Margin (MRQ) 10.51 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Y Mabs Therapeutics Inc's Segments
License    2.65 % of total Revenue
Product    100.86 % of total Revenue
Product Royalty Distribution agreement    10.07 % of total Revenue
United States Product    75.91 % of total Revenue
Ex-U S Product    24.95 % of total Revenue
Eastern Asia Product    9.17 % of total Revenue
Latin America Product    5.34 % of total Revenue
Western Asia Product    10.36 % of total Revenue
Other regions Product    0.08 % of total Revenue
DANYELZA    103.51 % of total Revenue
DANYELZA Product    100.86 % of total Revenue
DANYELZA License    2.65 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.